IMU shows announces promising response should run hard over next few days.
“We are pleased that there were no safety issues reported from the Cohort Review Committee. The early clinical data is also encouraging, indicating immune activation in vaccinated patients in a manner that is consistent with the vaccine’s postulated mechanism of action.”
